N/A N=15 Radiofrequency Ablation of Adenomyosis
Adenomyosis
Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
N/A N=161 Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.
Asherman Syndrome
Primary: The Zung Self-Rating Anxiety Scale Scores Before and After the Intervention — 36.4; 37.3; 32.1; 38.5 units on a scale(raw scores) — p=<0.001
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 2 N=141 Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion
Asherman Syndrome
Primary: the AFS Score at Second-look Hysteroscopy — 1.6; 1.9 units on a scale — p=>0.05
Early Phase 1 N=100 Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion
Endometrial Cancer
Primary: Percentage of Participants With Positive Predictive Value and Negative Predictive Value From Fluorescein Visualization — 71; 100; 85; 90 percentage of participants
Phase 2 N=567 Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Heavy Uterine Bleeding · Uterine Fibroids
Primary: Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month…
N/A N=300 Endometriosis and the Appendix - Incidence and Pathologic Analysis
Endometriosis of the Appendix
Primary: Incidence of Endometriosis of the Appendix — 23; 30 Participants — p=0.01
Phase 2 N=41 Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
Recurrent Pregnancy Loss · Unexplained Infertility
Primary: Abnormal Microbiome Bacterial Sequencing
Phase 3 N=241 PGL4001 Versus Placebo in Uterine Myomas
Uterine Myomas
Primary: Co-primary Endpoint: Percentage of Subjects With Reduction in Uterine Bleeding Defined as a Pictorial Blood-loss Assessment Chart (PBAC) Score <75 at End-of-treatment…
Phase 3 N=301 PGL4001 Versus GnRH-agonist in Uterine Myomas
Uterine Myomas
Primary: Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit…
Phase 3 N=157 A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Leiomyoma · Uterine Hemorrhage
Primary: Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment — 1.8; 47.2; 58.3 percentage of participants
N/A N=37 Evaluation of Uterine Patency Following Sonography-guided Transcervical Ablation of Fibroids
Uterine Fibroids · Adhesions
Primary: Number of Participants With Absence of Newly Formed Intrauterine Adhesions Following RF Ablation of Fibroids — 34 Participants
Phase 2 N=10 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation
N/A N=9 Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
Leiomyoma
Primary: Number and Type of Adverse Events — 15 Adverse Events
Phase 3 N=42 Trial of Mifepristone for Fibroids
Leiomyoma
Primary: Uterine Volume — 719; 449 mL
Phase 2 N=309 Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
Leiomyoma
Primary: Percentage of Subjects With Amenorrhea, Defined as no Scheduled or Unscheduled Bleeding/Spotting After the End of the Initial Bleeding Episode Until End of Treatment…
N/A N=3 Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata
Leiomyomata
Primary: Number of Participants With Serious Adverse Events — 0; 0 Participants
Phase 3 N=432 A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
Leiomyoma · Uterine Hemorrhage
Primary: Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 1 — 0.0; 42.0; 54.8 percentage of participants
Phase 2 N=42 Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
Leiomyoma
Primary: Shrinkage of Fibroids - Size of Fibroids — -0.27; -0.18; 0.07 logcm3 — p=0.43
Phase 3 N=662 Endometrial Safety Study
Postmenopause
Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants
Phase 3 N=451 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
Uterine Fibroids
Primary: Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses — 48.7; 60.5 percentage of subjects
Phase 4 N=74 Combined Vaginal Misoprostol and Perivascular Vasopressin
Leiomyoma · Laparoscopy · Uterine Myomectomy
Primary: Hemoglobin Levels Difference Between Pre and Post Surgery. — 0.76; 0.93 g/dL
N/A N=93 Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions
Asherman's Syndrome
Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009
N/A N=23 PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film
Intrauterine Adhesion
Primary: Safety (Adverse Events) — 0 device related adverse event
N/A N=56 Enriched Environments in Endometriosis
Endometriosis-related Pain · Endometriosis · Pelvic Pain
Primary: Pain Perception — 7.0; 6.2; 7.2; 5.1 units on a scale
Phase 4 N=12 Pilot of Letrozole for Uterine Myomas
Leiomyoma · Uterine Fibroids
Primary: Changes in Fibroid-related Symptoms After Treatment With Letrozole — -10.42; 1.43 units on a scale — p=0.24
N/A N=108 ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids
Uterine Fibroids
Primary: Percentage of Participants With Leg Pain or Lower Extremity Neuropathy Persisting or Occuring Greater Than 10 Days Following Treatment — 0 Percentage of participants